Skip to main content
Retour
RCUS logo

Arcus Biosciences, Inc.

Qualité des données : 100%
RCUS
NYSE Healthcare Biotechnology
20,25 €
▼ 1,16 € (-5,42%)
Cap. Boursière : 2,04B
Fourchette du Jour
20,15 € 20,98 €
Fourchette 52 Semaines
6,50 € 26,40 €
Volume
1 454 726
Moyenne 50J / 200J
21,61 € / 16,52 €
Clôture Précédente
21,41 €

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Healthcare (627 pairs)

Métrique Action Médiane du Secteur
P/E -5,8 0,3
P/B 3,2 2,9
ROE % -63,3 3,7
Net Margin % -142,9 3,8
Rev Growth 5Y % -10,4 10,0
D/E 0,2 0,2

Objectif de Cours des Analystes

Hold
28,00 € +38.3%
Low: 20,00 € High: 35,00 €
BPA Prévisionnel
-3,81 €
CA Est.
93 M

Estimations de Bénéfices

Période BPA Est. CA Est. Analystes
FY2030 1,70 €
0,09 € – 4,24 €
970 M 6
FY2029 -0,77 €
-1,93 € – -0,04 €
490 M 6
FY2028 -2,19 €
-2,83 € – -1,43 €
220 M 8

Points Clés

Revenue declined -10,39% annually over 5 years
Debt/Equity of 0,16 — conservative balance sheet
Negative free cash flow of -484,00M
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 6,13%
Capital efficient — spends only 0,81% of revenue on capex

Croissance

Revenue Growth (5Y)
-10,39%
Revenue (1Y)-4,26%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Qualité

Return on Equity
-63,26%
ROIC-39,66%
Net Margin-142,91%
Op. Margin-156,28%

Sécurité

Debt / Equity
0,16
Current Ratio4,36
Interest Coverage-48,25

Valorisation

P/E Ratio
-5,78
P/B Ratio3,23
EV/EBITDAN/A
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) -4,26% Revenue Growth (3Y) 45,30%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) -10,39% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 247,00M Net Income (TTM) -353,00M
ROE -63,26% ROA -30,99%
Gross Margin 95,95% Operating Margin -156,28%
Net Margin -142,91% Free Cash Flow (TTM) -484,00M
ROIC -39,66% FCF Growth (3Y) N/A
Safety
Debt / Equity 0,16 Current Ratio 4,36
Interest Coverage -48,25 Dividend Yield 0,00%
Valuation
P/E Ratio -5,78 P/B Ratio 3,23
P/S Ratio 8,25 PEG Ratio -1,52
EV/EBITDA N/A Dividend Yield 0,00%
Market Cap 2,04B Enterprise Value 1,92B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 247,00M 258,00M 117,00M 112,00M 383,00M
Net Income -353,00M -283,00M -307,00M -267,00M 53,00M
EPS (Diluted) -3,29 -3,14 -4,15 -3,71 0,71
Gross Profit 237,00M 258,00M 117,00M 112,00M 383,00M
Operating Income -386,00M -330,00M -340,00M -280,00M 54,00M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 1,14B 1,15B 1,10B 1,35B 1,59B
Total Liabilities 508,00M 665,00M 633,00M 688,00M 750,45M
Shareholders' Equity 631,00M 485,00M 462,00M 657,00M 841,45M
Total Debt 99,00M 60,00M 11,00M 120,00M 121,99M
Cash & Equivalents 222,00M 150,00M 127,00M 206,00M 147,91M
Current Assets 1,01B 1,02B 831,00M 1,07B 1,26B
Current Liabilities 231,00M 226,00M 184,00M 193,00M 166,08M